Jennifer L Taubert
CIK 1745938 · EVP, WWC. Innovative Medicine · last filed 2026-10-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
JNJ.WD price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08933
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MCD | Director | — | $235.23 | — | $0 | 15 | 2026-10-02 |
| JNJ | EVP, WWC. Innovative Medicine | 209,451 | $261.44 | $54.76M | -$17.55M | 12 | 2026-08-18 |
| JOHNSON & JOHNSON (JNJ.WD) Delisted | EVP, WWC. Innovative Medicine | 194,451 | — | — | -$19.32M | 11 | 2026-02-18 |
Recent Filings · Page 3 of 5
41 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-02-20 | JOHNSON & JOHNSON (JNJ.WD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-02-15 | JOHNSON & JOHNSON (JNJ.WD) Delisted | Mixed | +636 | -$105.1K | EDGAR |
| 2024-02-14 | JOHNSON & JOHNSON (JNJ.WD) Delisted | Mixed | +12,799 | -$2.11M | EDGAR |
| 2024-02-12 | JOHNSON & JOHNSON (JNJ.WD) Delisted | Mixed | +1,826 | -$4.21M | EDGAR |
| 2024-02-09 | JNJ | Notice (144) | −59,397 | -$9.28M | EDGAR |
| 2024-01-03 | MCD | Grant (A) | — | $0 | EDGAR |
| 2023-10-03 | MCD | Grant (A) | — | $0 | EDGAR |
| 2023-07-05 | MCD | Grant (A) | — | $0 | EDGAR |
| 2023-04-04 | MCD | Grant (A) | — | $0 | EDGAR |
| 2023-02-15 | JNJ | Mixed | +10,853 | -$1.71M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.